A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. It is an intermediate in the delta-5 pathway of biosynthesis of GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.
Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.
An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.
Saturated derivatives of the steroid pregnane. The 5-beta series includes PROGESTERONE and related hormones; the 5-alpha series includes forms generally excreted in the urine.
A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. It serves as an intermediate in the biosynthesis of HYDROCORTISONE and GONADAL STEROID HORMONES.
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.
A 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.

Apparent activities of 21-hydroxylase, 17alpha-hydroxylase and 17,20-lyase are impaired in adrenal incidentalomas. (1/52)

OBJECTIVE: An increased response of 17-hydroxyprogesterone to ACTH stimulation has been observed in adrenal incidentaloma and linked to an impairment of either 21-hydroxylase or of 11beta-hydroxylase activity. To analyse this question further, we investigated the steroidogenic pathways in a series of 17 adrenal incidentalomas. DESIGN AND PATIENTS: 17 patients (7 women, 10 men; mean age, 62 +/- 12 years) with non-histologically analyzed adrenal incidentalomas were prospectively evaluated. METHODS: The following variables were investigated: 24-h urinary methanephrines and free cortisol excretion; plasma levels of ACTH and dehydroepiandrosterone; overnight dexamethasone suppression test; 1-24 ACTH stimulation test with measurement of: cortisol, 11-deoxycortisol, 17-hydroxyprogesterone, aldosterone, 11-deoxycorticosterone, progesterone, 17-hydroxypregnenolone, Delta4-androstenedione, dehydroepiandrosterone and 21-deoxycortisol. RESULTS: Discordant features of subclinical hypercorticism were noted in one case. No patient had dehydroepiandrosterone sulfate levels in the normal range for his or her age. Peak 17-hydroxyprogesterone and peak 21-deoxycortisol disclosed impairment of 21-hydroxylase in 11 and 10 cases respectively. An increased 11-deoxycortisol/cortisol ratio identified reduced activity of 11beta-hydroxylase in 11 patients. Eight patients displayed features of mild 17,20-lyase impairment, which was related to 21-hydroxylase dysfunction. Whereas only 2 patients showed no enzyme modification, 9 displayed alterations of at least two pathways. CONCLUSION: In our hands, a combination of enzyme dysfunction was frequently observed. Shared biochemical mechanisms could explain combined 17,20-lyase and 21-hydroxylase alterations, whereas coexistence of 21-hydroxylase (particularly when based on peak 21-deoxycortisol) and 11beta-hydroxylase is more puzzling.  (+info)

Conversion of pregnenolone to DHEA by human 17alpha-hydroxylase/17, 20-lyase (P450c17). Evidence that DHEA is produced from the released intermediate, 17alpha-hydroxypregnenolone. (2/52)

Most previous studies using reconstituted systems and fast kinetics suggest that the conversion of pregnenolone to dehydroepiandrosterone (DHEA; the precursor of androgen and estrogen biosynthesis) by P450c17 does not require the release of the intermediate 17alpha-OHPreg (a precursor of cortisol biosynthesis). With such a mechanism, it is difficult to conceive how high amounts of DHEA may be produced in some cells or tissues, such as the testis and cells from the adrenal reticularis, while in other tissues such as the fasciculata zone, high levels of 17alpha-OHPreg are synthesized. In this report, we address this matter using intact transfected cells, which better reflect the actual cellular conditions. Furthermore, by using transfected cells, we can conveniently analyze human enzymes, as we are not restricted by the availability of human tissues as in the case of methods using purified or partially purified enzymes. Using intact HEK-293 cells transfected with human P450c17 in culture, we showed, in a time course study of the transformation of pregnenolone, that there is an accumulation of 17alpha-OHPreg, and that, subsequently, the accumulated 17alpha-OHPreg decreases with a concomitant increase in DHEA production. The DHEA/17alpha-OHPreg ratio changes from 0.1 :1 after 1 h incubation to 50 : 1 after 20 h. This result strongly suggests that the transformation of Preg to DHEA proceeds through two steps in which DHEA is produced from the released intermediate 17alpha-OHPreg. We also show that high levels of substrate vs. enzyme concentration will lead to high hydroxylase activity whereas the reverse will increase the lyase activity. The result is in good agreement with recent observations suggesting that surrounding enzymes and steroids could modulate the lyase activity. Cotransfection of vectors expressing cytochrome b5 and NADPH cytochrome P450 reductase indicates that both are required for an optimum production of DHEA.  (+info)

Serum concentrations of delta 5-3 beta-hydroxysteroids in type 2 diabetes mellitus. (3/52)

We examined the serum concentrations of delta(5)-3beta-hydroxysteroids, pregnenolone (Preg), 17-hydroxypregnenolone (17-OH-Preg), dehydroepiandrosterone (DHEA), androstenediol (ADIOL) and their sulfates in 30 well controlled (Group I: HbA1c<7.0%) and 15 poorly controlled (Group II: HbA1c>7.1%) type 2 diabetic patients, and 30 normal controls. These patients were treated with diet therapy or anti-diabetic agent. The distribution of gender and age of the subjects were matched between the groups. The serum levels of sulfo-conjugated and unconjugated steroids described above were measured by GC-MS and enzyme immunoassay (EIA), respectively. The serum levels of the entire sulfo-conjugated steroid measured in this study were significantly lower in Groups I and II than in controls. On the other hand, Preg levels in both Groups I and II were significantly higher than those in controls, whereas the serum levels of the downstream unconjugated steroids were not different from controls. To investigate the effect of sulfonylurea (SU) on the serum levels of steroids, the serum concentrations of steroids between the patients who were treated with diet therapy and SU agent were compared in Group I. No significant differences were observed between both groups. These results suggest that (1) since increased Preg levels did not cause any changes in the downstream delta(5)-3beta-hydroxysteroid levels, the metabolic pathway of delta(4)-3-ketosteroids may be accelerated in type 2 diabetes; (2) serum steroid levels were not affected by SU treatment; (3) sulfo-conjugated steroid catabolism was altered in type 2 diabetes; (4) the decreased sulfo-conjugated steroids especially ADIOLS may contribute to the alteration of sex steroid levels and onset or exacerbate infectious diseases in diabetes.  (+info)

Molecular dynamics of substrate complexes with hamster cytochrome P450c17 (CYP17): mechanistic approach to understanding substrate binding and activities. (4/52)

The cytochrome P450c17 isoforms from various animal species have different substrate selectivity, especially for 17,20-lyase activity. In particular, the human P450c17 selectively produces dehydroepiandrosterone with little androstenedione (AD). Hamster P450c17, on the other hand, produces both of these steroids at comparable rates. We thus investigated if computational analysis could explain the difference in activity profiles. Therefore, we inserted the four P450c17 substrates-pregnenolone, progesterone, and their 17alpha-hydroxylated forms-inside our hamster P450c17 model, which we derived from our human P450c17 model based on the crystal structure of P450BMP. We performed molecular dynamics (MD) simulations on the complexes and analyzed the resultant trajectories to identify amino acids that interact with substrates. Starting with substrates in two different orientations, we obtained two sets of binding trajectories in each case. The first set of trajectories reveal structural rearrangements that occur during binding, whereas the second set of trajectories reflects substrate orientations during catalysis. Our modeling suggests that three distinct steps are required for substrate selectivity and binding to the hamster P450c17: (1) recognition of the substrate at the putative substrate entrance, characterized by a pocket at the surface of the hamster P450c17 containing charged residues R96 and D116; (2) entry of the substrate into the active site, in an intermediate position directed by possible hydrogen bonding of the substrates with the heme D-ring propionate group, R96, R440, and T306; followed by (3) 90 degrees counterclockwise rotation of the substrates, positioning them in optimal position for reactivity, a process that may be directed by hydrogen bonding to the 110-112 region of the hamster P450c17. With some substrates, we obtained trajectories which suggest that major distortions in the I-helix and opening of the H-I loop occur during substrate binding. In conclusion, these modeling exercises provide insight to possible structural reorganizations that occur during substrate binding and suggest that amino acids that participate in three distinct steps of this process may all contribute to substrate binding and activity.  (+info)

Steroid hormone formation in bovine ovarian follicles. (5/52)

In an attempt to assess histophysiological implication of the follicular compartment of the bovine ovary in steroid hormone formation and the effect of human chorionic gonadotropin (hCG) in vitro on follicular steroidogenesis, minces of follicular tissues from non-gravid bovine ovaries were incubated with radioactive testosterone or acetate in the presence and absence of hCG. Significant amounts of estrone and estradiol-17beta were formed on incubation with testosterone-4-14C; hCG decreased the conversion approximately by 30%. The major radioactive products formed from acetate-l-14C were androstenedione and testosterone with lesser amounts of dehydroepiandrosterone and 17-hydroxyprogesterone. In addition, small amounts of progesterone, 17-hydroxypregnenolone, estrone and estradiol-17beta were formed. Histology of the dissected follicle specimens was characterized by dominant theca cells undergoing luteinization with small amounts of granulosa cells, which showed neither proliferation nor luteinization. The pattern of distribution of radioactivity among the steroids formed from acetate-14C was considered to represent steroidogenic profile of bovine atretic follicles. The addition of hCG in vitro increased the overall incorporation of radioactive acetate into the steroids approximately by 50%, although the range of increase was not uniform in the individual steroids under the exprimental conditions.  (+info)

Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). (6/52)

Although the human sebaceous gland can synthesize cholesterol from acetate and can further metabolize steroids such as dehydroepiandrosterone into potent androgens, the de novo production of steroids from cholesterol has not been demonstrated in human skin. The goal of this study was to delineate the steroidogenic pathway upstream from dehydroepiandrosterone by documenting the presence of members of the P450 side chain cleavage system (P450scc). This system catalyzes the initial step in steroid hormone synthesis following translocation of cholesterol to the inner mitochondrial membrane. In concert with its cofactors, adrenodoxin and adrenodoxin reductase, and the transcription factor steroidogenic factor 1, P450scc converts cholesterol to pregnenolone. An SV40 immortalized human sebaceous gland cell line (SEB-1) was established in order to facilitate investigation of the P450scc system. The sebaceous phenotype of SEB-1 sebocytes was confirmed using immunohistochemistry, Oil Red O staining, and gene array expression analysis. Presence of P450scc, adrenodoxin reductase, cytochrome P450 17-hydroxylase (P450c17), and steroidogenic factor 1 was documented in human facial skin, human sebocytes, and SEB-1 sebocytes. Using immunohistochemistry, antibodies to the above proteins localized to epidermis, hair follicles, sebaceous ducts, and sebaceous glands in sections of facial skin. Results of immunohistochemistry were confirmed with Western blotting. Biochemical activity of cytochrome P450scc and P450c17 was demonstrated in SEB-1 sebocytes using radioimmunoassay. The relative abundance of mRNA for P450scc, P450c17, and steroidogenic factor 1 in SEB-1 sebocytes and sebaceous glands was compared to mRNA levels in ovarian theca and granulosa cells using real-time quantitative polymerase chain reaction. Gene array expression analysis and quantitative polymerase chain reaction indicated that mRNA for P450scc is more abundant than mRNA for both P450c17 and steroidogenic factor 1 in sebaceous glands and SEB-1 cells. These data demonstrate that the skin is in fact a steroidogenic tissue. The clinical significance of this finding in mediating androgenic skin disorders such as acne, hirsutism, or androgenetic alopecia remains to be established.  (+info)

Steroid hormone formation in human ovarian follicles in vitro. (7/52)

Ovarian follicles of 5 to 15 mm in diameter were isolated from 45 ovaries of 34 patients in the follicular and luteal phases of the cycle. Three experiments were done. In the first, follicles were minced and incubated in Krebs-Ringer bicarbonate buffer containing 1 to 2muCi of testosterone-4-14C in the presence or absence of 100 IU human chorionic gonadotropan (hCG). In the second, minced follicles were incubated with 100 muCi of sodium acetate-I-14C under identical conditions. In the third, ten follicles from a single patient in the late proliferative stage of endometrial dating were cut in halves and incubated with 100 muCi of acetate-I-14C under identical conditions. The minced follicle preparation was capable of aromatizing testosterone-4-14C into radioactive estrone and estradiol in significant amounts. Incorporation of radioactive acetate into pregenolone, progesterone, 17-hydroxypregnenolone, 17-hydroxyprogesterone, dehydroepiandrosterone, androstenedione, testosterone, estradiol and estrone was assessed by reverse dilution analysis with recrystallization to constant specific activity. The major radioactive products formed were androstenedione and 17-hydroxyprogesterone in the latter two experiments. Dehydroepiandrosterone was one of the major steroids in the second experiment. The minor products were testosterone, progesterone and pregnenolone. Smaller, but definite incorporations of radioactive acetate into estradiol and estrone occurred in the second experiment. On histological examination, the follicles were characterized by atretic changes. This distribution pattern of radioactive acetate among the steroids was considered to represent the steroidogenic profile of unstimulated or atretic follicles.  (+info)

Neurosteroid metabolism. 7 alpha-Hydroxylation of dehydroepiandrosterone and pregnenolone by rat brain microsomes. (8/52)

Two 'neurosteroids', dehydroepiandrosterone (DHEA) and pregnenolone (PREG), are converted by rat brain microsomes into polar metabolites, identified as the respective 7 alpha-hydroxylated (7 alpha-OH) derivatives by the 'twin ion' technique of g.l.c.-m.s. with deuterated substrates. The enzymic reaction requires NADPH and is stimulated 2-4-fold by EDTA. Under optimal conditions (pH 7.4, 0.5 mM-NADPH, 1 mM-EDTA), the Km values for DHEA and PREG are 13.8 and 4.4 microM respectively, and the Vmax. values are 322 and 38.8 pmol/min per mg of microsomal protein respectively. Trace amounts of putative 7 beta-OH derivatives of DHEA and PREG are detected. Oestradiol, at a pharmacological concentration of 5 microM, inhibits DHEA and PREG 7 alpha-hydroxylation. Formation of 7 alpha-hydroxylated metabolites is low in prepubertal rats and increases 5-fold in adults. Derivatives of PREG and DHEA, such as PREG sulphate, DHEA sulphate, progesterone and 3 alpha-hydroxy-5 alpha-pregnan-20-one, are known to be neuroactive. Therefore the quantitatively important metabolism to 7 alpha-OH compounds may contribute to the control of neurosteroid activity in brain.  (+info)

17-alpha-Hydroxypregnenolone is a steroid hormone that is produced in the adrenal glands and, to a lesser extent, in the gonads (ovaries and testes). It is an intermediate in the biosynthesis of steroid hormones, including cortisol, aldosterone, and sex hormones such as testosterone and estrogen.

17-alpha-Hydroxypregnenolone is formed from pregnenolone through the action of the enzyme 17α-hydroxylase. It can then be converted to 17-hydroxyprogesterone, which is a precursor to both cortisol and androgens such as testosterone.

While 17-alpha-Hydroxypregnenolone itself does not have significant physiological activity, its role in the biosynthesis of other steroid hormones makes it an important intermediate in the endocrine system. Dysregulation of its production or metabolism can contribute to various medical conditions, such as congenital adrenal hyperplasia and certain forms of cancer.

Hydroxyprogesterone is a synthetic form of the natural hormone progesterone, which is produced by the body during pregnancy to support the growth and development of the fetus. Hydroxyprogesterone is used in medical treatments to help prevent preterm birth in certain high-risk pregnancies.

There are several different forms of hydroxyprogesterone that have been developed for use as medications, including:

1. Hydroxyprogesterone caproate (HPC): This is a synthetic form of progesterone that is given as an injection once a week to help prevent preterm birth in women who have previously given birth prematurely. It works by helping to thicken the lining of the uterus and prevent contractions.
2. 17-Hydroxyprogesterone: This is a natural hormone that is produced by the body during pregnancy, but it can also be synthesized in a laboratory for use as a medication. It has been studied for its potential to help prevent preterm birth, although it is not currently approved for this use by the U.S. Food and Drug Administration (FDA).
3. 21-Hydroxyprogesterone: This is another natural hormone that is produced by the body during pregnancy, but it can also be synthesized in a laboratory for use as a medication. It has been studied for its potential to help prevent preterm birth and for its ability to reduce the risk of certain complications in women with a history of premature birth.

It's important to note that hydroxyprogesterone should only be used under the supervision of a healthcare provider, as it can have side effects and may not be appropriate for all women. If you are pregnant or planning to become pregnant and have concerns about preterm birth, it's important to discuss your options with your healthcare provider.

Fluoxymesterone is a synthetic androgenic anabolic steroid hormone. It is derived from testosterone and has been structurally modified to increase its androgenic effects while reducing its estrogenic and progestogenic activity. Fluoxymesterone is used in medical treatment for conditions such as hypogonadism, delayed puberty, and breast cancer in women. It works by replacing the missing testosterone in men or mimicking the effects of testosterone in the body.

Fluoxymesterone is known to have a high anabolic and androgenic activity, and it is commonly abused for non-medical purposes such as improving physical performance, muscle mass, and strength. However, its use for these purposes is not approved by regulatory agencies and can lead to serious health consequences.

Fluoxymesterone is available in oral form and is typically taken two to three times a day due to its short half-life. Its side effects may include acne, hair loss, liver toxicity, mood changes, aggression, and changes in sexual function. It is important to use this medication under the supervision of a healthcare provider and follow their instructions carefully to minimize the risk of adverse effects.

Pregnanes are a class of steroid hormones and steroids that contain a pregnane nucleus, which is a steroid core with a carbon skeleton consisting of 21 carbons. This structure includes four fused rings, labeled A through D, and is derived from cholesterol.

Pregnanes are important precursors for the synthesis of various steroid hormones in the body, including progesterone, which plays a crucial role in maintaining pregnancy and regulating the menstrual cycle. Other examples of pregnanes include cortisol, a stress hormone produced by the adrenal gland, and aldosterone, a hormone that helps regulate electrolyte balance and blood pressure.

It's worth noting that pregnanes can also refer to synthetic compounds that contain this steroid nucleus and are used in various medical and research contexts.

17-α-Hydroxyprogesterone is a naturally occurring hormone produced by the adrenal glands and, in smaller amounts, by the ovaries and testes. It is an intermediate in the biosynthesis of steroid hormones, including cortisol, aldosterone, and sex hormones such as testosterone and estrogen.

In a medical context, 17-α-Hydroxyprogesterone may also refer to a synthetic form of this hormone that is used in the treatment of certain medical conditions. For example, a medication called 17-alpha-hydroxyprogesterone caproate (17-OHP) is used to reduce the risk of preterm birth in women who have previously given birth prematurely. It works by suppressing uterine contractions and promoting fetal lung maturity.

It's important to note that 17-alpha-Hydroxyprogesterone should only be used under the supervision of a healthcare provider, as it can have side effects and may interact with other medications.

Dehydroepiandrosterone (DHEA) is a steroid hormone produced by the adrenal glands. It serves as a precursor to other hormones, including androgens such as testosterone and estrogens such as estradiol. DHEA levels typically peak during early adulthood and then gradually decline with age.

DHEA has been studied for its potential effects on various health conditions, including aging, cognitive function, sexual dysfunction, and certain chronic diseases. However, the evidence supporting its use for these purposes is generally limited and inconclusive. As with any supplement or medication, it's important to consult with a healthcare provider before taking DHEA to ensure safety and effectiveness.

I am not aware of a medical definition for "Cortodoxone." It is possible that this term is not recognized in the field of medicine as it does not appear to be a commonly used medication, treatment, or diagnostic tool. If you have any more information about where you encountered this term or its potential meaning, I would be happy to try and provide further clarification.

Pregnenolone is defined as a steroid hormone produced in the body from cholesterol. It's often referred to as the "mother hormone" since many other hormones, including cortisol, aldosterone, progesterone, testosterone, and estrogen, are synthesized from it.

Pregnenolone is primarily produced in the adrenal glands but can also be produced in smaller amounts in the brain, skin, and sex organs (ovaries and testes). It plays a crucial role in various physiological processes such as maintaining membrane fluidity, acting as an antioxidant, and contributing to cognitive function.

However, it's important to note that while pregnenolone is a hormone, over-the-counter supplements containing this compound are not approved by the FDA for any medical use or condition. As always, consult with a healthcare provider before starting any new supplement regimen.

Radioimmunoassay (RIA) is a highly sensitive analytical technique used in clinical and research laboratories to measure concentrations of various substances, such as hormones, vitamins, drugs, or tumor markers, in biological samples like blood, urine, or tissues. The method relies on the specific interaction between an antibody and its corresponding antigen, combined with the use of radioisotopes to quantify the amount of bound antigen.

In a typical RIA procedure, a known quantity of a radiolabeled antigen (also called tracer) is added to a sample containing an unknown concentration of the same unlabeled antigen. The mixture is then incubated with a specific antibody that binds to the antigen. During the incubation period, the antibody forms complexes with both the radiolabeled and unlabeled antigens.

After the incubation, the unbound (free) radiolabeled antigen is separated from the antibody-antigen complexes, usually through a precipitation or separation step involving centrifugation, filtration, or chromatography. The amount of radioactivity in the pellet (containing the antibody-antigen complexes) is then measured using a gamma counter or other suitable radiation detection device.

The concentration of the unlabeled antigen in the sample can be determined by comparing the ratio of bound to free radiolabeled antigen in the sample to a standard curve generated from known concentrations of unlabeled antigen and their corresponding bound/free ratios. The higher the concentration of unlabeled antigen in the sample, the lower the amount of radiolabeled antigen that will bind to the antibody, resulting in a lower bound/free ratio.

Radioimmunoassays offer high sensitivity, specificity, and accuracy, making them valuable tools for detecting and quantifying low levels of various substances in biological samples. However, due to concerns about radiation safety and waste disposal, alternative non-isotopic immunoassay techniques like enzyme-linked immunosorbent assays (ELISAs) have become more popular in recent years.

Alpha 1-antitrypsin (AAT, or α1-antiproteinase, A1AP) is a protein that is primarily produced by the liver and released into the bloodstream. It belongs to a group of proteins called serine protease inhibitors, which help regulate inflammation and protect tissues from damage caused by enzymes involved in the immune response.

Alpha 1-antitrypsin is particularly important for protecting the lungs from damage caused by neutrophil elastase, an enzyme released by white blood cells called neutrophils during inflammation. In the lungs, AAT binds to and inhibits neutrophil elastase, preventing it from degrading the extracellular matrix and damaging lung tissue.

Deficiency in alpha 1-antitrypsin can lead to chronic obstructive pulmonary disease (COPD) and liver disease. The most common cause of AAT deficiency is a genetic mutation that results in abnormal folding and accumulation of the protein within liver cells, leading to reduced levels of functional AAT in the bloodstream. This condition is called alpha 1-antitrypsin deficiency (AATD) and can be inherited in an autosomal codominant manner. Individuals with severe AATD may require augmentation therapy with intravenous infusions of purified human AAT to help prevent lung damage.

... alpha subunit MeSH D06.472.351.576.463 - luteinizing hormone MeSH D06.472.351.576.463.249 - glycoprotein hormones, alpha ... 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 - 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 - ... alpha-msh MeSH D06.472.699.631.525.690.583.075 - beta-msh MeSH D06.472.699.631.525.690.583.115 - gamma-msh MeSH D06.472.699.631 ... alpha-msh MeSH D06.472.734.525.690.583.075 - beta-msh MeSH D06.472.734.525.690.583.115 - gamma-msh MeSH D06.472.734.525.883 - ...
MeSH D04.345.051.500 - crown ethers MeSH D04.345.103.222 - alpha-cyclodextrins MeSH D04.345.103.333 - beta-cyclodextrins MeSH ... 20-alpha-dihydroprogesterone MeSH D04.808.745.745.654.829.395 - hydroxyprogesterones MeSH D04.808.745.745.654.829.395.400 - 17- ... 5-alpha-dihydroprogesterone MeSH D04.808.745.558.050 - alfaxalone alfadolone mixture MeSH D04.808.745.558.783 - ... alpha-hydroxyprogesterone MeSH D04.808.745.745.654.829.614 - medroxyprogesterone MeSH D04.808.745.745.654.829.614.500 - ...
"Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive ... It has both 17α-hydroxylase and 17,20-lyase activities, and is a key enzyme in the steroidogenic pathway that produces ... CYP17A1 has both 17α-hydroxylase activity (EC 1.14.14.19) and 17,20-lyase activity (EC 1.14.14.32). The 17α-hydroxylase ... Cytochrome b5 acts as a facilitator for 17,20 lyase activity of CYP17A1 and can donate a second electron to some P450s. In ...
"DHEA metabolites activate estrogen receptors alpha and beta". Steroids. 78 (1): 15-25. doi:10.1016/j.steroids.2012.10.002. PMC ... "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". ... Thus, 17,20-lyase is required for the synthesis of androstenedione, whether immediately or one step removed. Androstenedione is ... Androstenedione, or 4-androstenedione (abbreviated as A4 or Δ4-dione), also known as androst-4-ene-3,17-dione, is an endogenous ...
"Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive ... Some persons with 17α-hydroxylase deficiency develop hypertension in infancy, and nearly 90% do so by late childhood. The low- ... 17α-hydroxylase deficiency in genetic males (XY) results in moderate to severe reduction of fetal testosterone production by ... This form of CAH results from deficiency of the enzyme 17α-hydroxylase (also called CYP17A1). It accounts for less than 5% of ...
These progestogens, along with another steroid, 17α-hydroxypregnenolone, are the precursors of all other endogenous steroids, ... Major examples of progestins include the 17α-hydroxyprogesterone derivative medroxyprogesterone acetate and the 19- ... 17-alpha hydroxyprogesterone caproate, and related progestins". Am. J. Obstet. Gynecol. 197 (6): 599.e1-7. doi:10.1016/j.ajog. ... 17α-OHP) (very weak), 20α-dihydroprogesterone (20α-DHP), 20β-dihydroprogesterone (20β-DHP), 5α-dihydroprogesterone (5α-DHP), 5β ...
Sharquie KE, Noaimi AA, Saleh BO, Anbar ZN (December 2009). "The frequency of 21-alpha hydroxylase enzyme deficiency and ... The cutoff basal 17-OHP value is matter of debate. Most commonly, the value of 2.0 ng/mL is used, but a value of 1.7 ng/mL ... Biochemical parameters like 17α-hydroxyprogesterone may not be elevated in very mild cases of LOCAH, and may vary between labs ... 17-OHP levels over 10 ng/mL at the 60th minute post stimulation is considered diagnostic for LOCAH. In 21-hydroxylase ...
Finally, a deficiency in the related 3-alpha-hydrozysteroid dehydrogenase may also play a role in hirsutism. 3-alpha HSD is ... Deficient 3-alpha HSD activity may lead to increased tissue levels of DHT and subsequent hirsutism. [11] ... 17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ... 17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ...
Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in ... genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17alpha-hydroxylase/17,20-lyase ... 17 alpha-hydroxylase/17,20-lyase deficiency. Dozens of mutations in the CYP17A1 gene have been found to cause 17α-hydroxylase/ ... As a result, 17,20-lyase activity is severely reduced but 17α-hydroxylase activity is normal. As in 17α-hydroxylase/17,20-lyase ...
... alpha subunit MeSH D06.472.351.576.463 - luteinizing hormone MeSH D06.472.351.576.463.249 - glycoprotein hormones, alpha ... 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 - 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 - ... alpha-msh MeSH D06.472.699.631.525.690.583.075 - beta-msh MeSH D06.472.699.631.525.690.583.115 - gamma-msh MeSH D06.472.699.631 ... alpha-msh MeSH D06.472.734.525.690.583.075 - beta-msh MeSH D06.472.734.525.690.583.115 - gamma-msh MeSH D06.472.734.525.883 - ...
2. 17-OHPREG is then converted to 17-hydroxyprogesterone (17-OHP) by the enzyme 3-beta-hydroxysteroid dehydrogenase (3β-HSD). ... 3. Finally, 17-OHP is converted to progesterone by the enzyme 21-hydroxylase. ... 1. PDG is converted to 17-hydroxypregnenolone (17-OHPREG) through the action of the enzyme 17-alpha-hydroxylase. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
20-alpha-Dihydroprogesterone. Hydroxypregnenolone. 17-alpha-Hydroxypregnenolone. Prasterone. Dehydroepiandrosterone. Stanolone ... 5,8,11,14,17-Eicosapentaenoic Acid. Eicosapentaenoic Acid. D12 - AMINO ACIDS, PEPTIDES, AND PROTEINS. Mercaptopropionylglycine ... Androst-5-ene-3 beta,17 beta-diol. Androstenediol. Dihydroprogesterone. ...
17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ... 3BHSD catalyzes the conversion of pregnenolone to progesterone (mineralocorticoid pathway), 17-alpha-hydroxypregnenolone to 17- ... alpha-hydroxyprogesterone (glucocorticoid pathway), and dehydroepiandrosterone to androstenedione (sex steroid pathway). ... Exogenous glucocorticoid therapy suppresses adrenocorticotropic hormone (ACTH) secretion and decreases pregnenolone, 17- ...
Increased concentration of 17alpha-hydroxypregnenolone in the blood circulation. 17alpha-hydroxypregnenolone is a 21-carbon ... Elevated circulating 17-hydroxyprogesterone concentration. MedGen UID: 1613419. •Concept ID: C4531273. •. Finding. ... Increased circulating 17 hydroxypregnenolone concentration. MedGen UID: 1788603. •Concept ID: C5539825. •. Finding. ... 17-hydroxyprogesterone is an intermediate steroid in the adrenal biosynthetic pathway from cholesterol to cortisol and is the ...
Steroid 16-alpha-Hydroxylase is an enzyme that catalyzes the reaction adding a hydroxyl group to the sixteen (16) alpha ... Steroid 16-alpha-Hydroxylase is an enzyme that catalyzes the hydroxylation of C16 position in steroids, playing a crucial role ... Cytochrome a1 contains a heme with a formyl group at the 2 position (heme a) and has an alpha band in its absorption spectrum ... They consist of a central carbon atom, also known as the alpha carbon, which is bonded to an amino group (-NH2), a carboxyl ...
17alpha-hydroxypregn-5-ene-3,20-dione 17alpha-hydroxypregnenolone + 17alpha-hydroxypregnenolone 3-sulfate ... 8-demethyl-8-(2,3,4-O-trimethyl-alpha-L-rhamnosyl)tetracenomycin C ... 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione ... 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione ; 9-Fluoro-16beta-methylprednisolone ; 9alpha- ...
5 alpha-pregnan-3 alpha,20 alpha-diol behaves like a partial agonist in the modulation of GABA-stimulated chloride ion uptake ... 17alpha) monsulfate (FDR p value = 0.04). All Bonferroni and FDR significant steroid metabolites were projected onto KEGG ... steroids included pregnenolone that mediates biosynthesis of corticosteroids and progesterone and 21-hydroxypregnenolone ... and alpha keto glutarate as well as lactate where in females there was increase with higher power with no FDR significant ...
Females with 17-hydroxylase deficiency appear phenotypically female at birth but do not develop breasts or menstruate in ... CYP21A is the gene that codes for 21-hydroxylase, CYP11B1 codes for 11-beta-hydroxylase, and CYP17 codes for 17-alpha- ... Basal 17-hydroxyprogesterone cannot accurately predict nonclassical congenital adrenal hyperplasia in children and adolescents ... Hypertensive forms of adrenal hyperplasia (ie, 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency) are ...
17a-Hydroxypregnenolone. Estrone. Phosphoadenosine. phosphosulfate. Estrone sulfate. Adenosine 3,5-diphosphate. 19-Oxoandrost ... alpha-steroid. 4-dehydrogenase. 1. UDP-. glucuronosyltransferase. 2B17. Steryl-. sulfatase. 17-Hydroxyprogesterone. ... 17-β-Estradiol-3-glucuronide. Uridine 5-diphosphate. Accumulation. Androstenedione. O. 2. H. 2. O. NAD. NADH. Accumulation. ... ene-3,17-dione. Estradiol. NADP. NADPH. 19-Oxotestosterone. 19-Hydroxyandrost-4-ene-. 3,17-dione. 19-Hydroxytestosterone. ...
The syndrome of 17,20 lyase deficiency. J Clin Endocrinol Metab. 2012 Jan. 97(1):59-67. [QxMD MEDLINE Link]. [Full Text]. ... Females with 17-hydroxylase deficiency appear phenotypically female at birth but do not develop breasts or menstruate in ... CYP21A is the gene that codes for 21-hydroxylase, CYP11B1 codes for 11-beta-hydroxylase, and CYP17 codes for 17-alpha- ... Hypertensive forms of adrenal hyperplasia (ie, 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency) are ...
3-Keto-5-alpha-Steroid delta-4-Dehydrogenase use Testosterone 5-alpha-Reductase ... 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid ... 6-Oxo-PGF1 alpha use 6-Ketoprostaglandin F1 alpha 6-Oxoprostaglandin F1 alpha use 6-Ketoprostaglandin F1 alpha ...
... migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha ... Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus ...
Alpha-blockers (16) * Alpha-glucosidase inhibitors (1) * Amlodipine (13) * Amoxicillin (2) * Anastrozole (1) ...
In this study, we first identified 7alpha-hydroxypregnenolone and its stereoisomer 7beta-hydroxypregnenolone in quail brain. ... After infection, levels of interferon alpha and beta (IFN-α and IFN-ß) in the blood of macaques in the baloxavir group were the ... Subsequently, we demonstrated diurnal changes in 7alpha-hydroxypregnenolone synthesis in quail. 7Alpha-Hydroxypregnenolone ... 7Alpha-hydroxypregnenolone mediates melatonin action underlying diurnal locomotor rhythms. Tsutsui, Kazuyoshi; Inoue, Kazuhiko ...
Here, we examined in detail the processivity of the 17α-hydroxylation and lyase steps. b5 did not enhance reaction rates by ... S)-Orteronel was three times more inhibitory toward the conversion of 17α-hydroxypregnenolone to DHEA than toward the 17α- ... Abstract: Cytochrome P450 (P450, CYP) 17A1 plays a critical role in steroid metabolism, catalyzing both the 17α-hydroxylation ... IC50 values for (S)-orteronel were identical for blocking DHEA formation from pregnenolone and for 17α-hydroxylation, ...
High levels of 17-hydroxypregnenolone (Δ517OHP) are characteristic, but extra-adrenal conversion to 17 … ... 2019 Sep 17;20(18):4605. doi: 10.3390/ijms20184605. Int J Mol Sci. 2019. PMID: 31533357 Free PMC article. Review. ... High levels of 17-hydroxypregnenolone (Δ517OHP) are characteristic, but extra-adrenal conversion to 17-hydroxyprogesterone ( ...
... alpha-Defensins D12.644.276.87.44 D12.776.467.87.125 D23.529.87.48 alpha-Endorphin D12.776.641.650.405.935.119 D12.776.631.650. ... alpha-Synuclein D12.776.641.860.500 D12.776.631.860.500 D12.776.637.500 alpha-Tocopherol D3.438.150.909.750.249 D3.633.100.150. ... HLA-DP alpha-Chains D12.776.543.550.423.400.420.500 D12.776.543.550.440.400.420.500 HLA-DP Antigens D12.776.543.550.423.400.420 ... HLA-DR alpha-Chains D12.776.543.550.423.400.440.100 D12.776.543.550.440.400.440.100 HLA-DR Antigens D12.776.543.550.423.400.440 ...
17alpha)-Isomer 17alpha Hydroxypregnenolone 17alpha-Hydroxypregnenolone Hydroxypregnenolone 17-Hydroxypregnenolone, (3beta, ... 17alpha)-Isomer. 17alpha Hydroxypregnenolone. 17alpha-Hydroxypregnenolone. Hydroxypregnenolone. Tree number(s):. D04.210. ... 17alpha-Hydroxypregnénolone Entry term(s):. 17 Hydroxypregnenolone. 17 alpha Hydroxypregnenolone. 17 alpha-Hydroxypregnenolone ... 13alpha,17alpha)-Isomer - Narrower Concept UI. M0317865. Preferred term. 17-Hydroxypregnenolone, (3beta,13alpha,17alpha)-Isomer ...
17alpha)-Isomer 17alpha-Hydroxypregnenolone Hydroxypregnenolone Registry Number. 387-79-1. Related Numbers. 1887-95-2. 19454-90 ... 17alpha-Hydroxypregnenolone Term UI T527750. Date12/06/2002. LexicalTag NON. ThesaurusID NLM (2004). ... Hydroxypregnenolone Term UI T020789. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1964). ... 2004; see HYDROXYPREGNENOLONE 1972-2003; 17-HYDROXYPREGNENOLONE was indexed under HYDROXYPREGNENOLONE (NM) 1981-2003. History ...
17alpha)-Isomer 17alpha-Hydroxypregnenolone Hydroxypregnenolone Registry Number. 387-79-1. Related Numbers. 1887-95-2. 19454-90 ... 17alpha-Hydroxypregnenolone Term UI T527750. Date12/06/2002. LexicalTag NON. ThesaurusID NLM (2004). ... Hydroxypregnenolone Term UI T020789. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1964). ... 2004; see HYDROXYPREGNENOLONE 1972-2003; 17-HYDROXYPREGNENOLONE was indexed under HYDROXYPREGNENOLONE (NM) 1981-2003. History ...
17-hydroxycorticosteroid (substance) {112116001 , SNOMED-CT } Pregnenolone (substance) {47350002 , SNOMED-CT } Progesterone ...
Finally, a deficiency in the related 3-alpha-hydrozysteroid dehydrogenase may also play a role in hirsutism. 3-alpha HSD is ... Deficient 3-alpha HSD activity may lead to increased tissue levels of DHT and subsequent hirsutism. [9] ... 17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ... 17OH Preg = 17-alpha-hydroxypregnenolone; DHEA = Dehydroepiandrosterone; 17OH Prog = 17-alpha-hydroxyprogesterone; Andros = ...
... alpha 1-Antitrypsin N0000169495 alpha Catenin N0000169678 alpha Karyopherins N0000170004 alpha-2-Antiplasmin N0000183458 alpha- ... alpha-Galactosidase N0000178561 alpha-Globins N0000007645 Alpha-Globulins N0000167711 alpha-Glucosidases N0000167712 alpha-L- ... alpha-Macroglobulins N0000167728 alpha-Mannosidase N0000005770 alpha-Methyltyrosine N0000170379 alpha-MSH N0000167718 alpha-N- ... alpha-Crystallins N0000168521 alpha-Cyclodextrins N0000170294 alpha-Defensins N0000170405 alpha-Endorphin N0000171366 alpha- ...
GTP-Binding Protein alpha Subunits, Gi-Go MH old = G-Protein, Stimulatory Gs [P] MH new = GTP-Binding Protein alpha Subunits, ... Hydroxypregnenolone [N] MH new = 17-alpha-Hydroxypregnenolone MH old = 17-Hydroxyprogesterone [P] MH new = 17-alpha- ... Pregnancy-Associated alpha-Plasma Protein [N] MH new = Pregnancy-Associated Plasma Protein-A MH old = Pregnancy-Associated beta ... alpha-Mannosidosis MH old = Meckels Diverticulum [N] MH new = Meckel Diverticulum MH old = Mercaptopropionylglycine [P] MH new ...
... alpha-Defensins D12.644.276.87.44 D12.776.467.87.125 D23.529.87.48 alpha-Endorphin D12.776.641.650.405.935.119 D12.776.631.650. ... alpha-Synuclein D12.776.641.860.500 D12.776.631.860.500 D12.776.637.500 alpha-Tocopherol D3.438.150.909.750.249 D3.633.100.150. ... HLA-DP alpha-Chains D12.776.543.550.423.400.420.500 D12.776.543.550.440.400.420.500 HLA-DP Antigens D12.776.543.550.423.400.420 ... HLA-DR alpha-Chains D12.776.543.550.423.400.440.100 D12.776.543.550.440.400.440.100 HLA-DR Antigens D12.776.543.550.423.400.440 ...
20-lyase activity, which converts 17-hydroxypregnenolone to dehydroepiandrosterone (DHEA). This reaction is integral to the ... One, 3BetaHydroxy-Androst-5-Ene-17-One, Androstenolone, Dehydroepiandrosterone, Déhydroépiandrostérone, DHEA-S, GL701, ...
Both forms of adrenal hyperplasia are accompanied by elevated levels of 24-hour urinary 17-ketosteroids, the urinary ... Basal 17-hydroxyprogesterone cannot accurately predict nonclassical congenital adrenal hyperplasia in children and adolescents ... 2] For example, the distinguishing characteristic of 21-hydroxylase deficiency is a high serum concentration of 17- ... In contrast, hypertensive forms of adrenal hyperplasia (ie, 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency ...
... alpha Catenin alpha Karyopherins Alpha Particles Alpha Rhythm alpha-2-Antiplasmin alpha-2-HS-Glycoprotein Alpha-Amanitin alpha- ... alpha-Cyclodextrins alpha-Defensins alpha-Endorphin alpha-Fetoproteins alpha-Galactosidase alpha-Globins Alpha-Globulins alpha- ... alpha-L-Fucosidase alpha-Linolenic Acid alpha-Macroglobulins alpha-Mannosidase alpha-Mannosidosis alpha-Methyltyrosine alpha- ... Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-2 Receptor Antagonists Adrenergic alpha-Agonists Adrenergic alpha- ...
AB - The complete nucleotide sequence is reported of the two adult chicken alpha globin genes, alpha A and alpha D. These two ... XVII. The effect of marasmic acid on nucleic acid metabolism. AB - From submerged cultures of Lachnella villosa, Lachnella sp. ... hydroxypregnenolone and dehydroepiandrosterone in both the siblings, while testosterone (T) rose poorly in the brother, and ... Linkage of the A alpha and gamma chain genes. AB - We have utilized cDNA probes for the alpha, beta, and gamma chains of rat ...
Alpha-thalassemia X-linked ID syndrome XL. Distinctive craniofacial features, genital anomalies, hypotonia, severe ID, mild-to- ... 5-alpha-reductase deficiency (OMIM 264600). AR. Interferes w/conversion of testosterone to dihydrotestosterone causing possible ... moderate anemia secondary to alpha-thalassemia. DHCR7 Smith-Lemli-Opitz syndrome AR. Pre- & postnatal growth restriction, ... 17-alpha-hydroxylase deficiency / 17,20-lyase deficiency (OMIM 202110). AR. Hypertension, hypokalemic alkalosis, ↑ ACTH, LH & ...
Females with 17-hydroxylase deficiency appear phenotypically female at birth but do not develop breasts or menstruate in ... CYP21A is the gene that codes for 21-hydroxylase, CYP11B1 codes for 11-beta-hydroxylase, and CYP17 codes for 17-alpha- ... Basal 17-hydroxyprogesterone cannot accurately predict nonclassical congenital adrenal hyperplasia in children and adolescents ... Hypertensive forms of adrenal hyperplasia (ie, 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency) are ...
Validation of a new yeast-based reporter assay consisting of human estrogen receptors alpha/beta and coactivator SRC-1: ... hydroxypregnenolone (HPREG), dehydroepiandrosterone (DHEA), progesterone (PROG), 17〈-hydroxyprogesterone (HPROG), ... For CORT, two parameters (k17, q27) were highly sensitive at each MET dose, and five parameters (k2, k3, k26, q40, q42) were ... The model consists of 14 transport equilibrium constants (q19, q20, . . ., q32), 17 metabolic rate constants (k2, k3, . . ., k ...
We used intraclass correlation and Cronbachs alpha to examine the test-retest and internal consistency reliability of the QPR- ... 7α-hydroxypregnenolone (7α-OH-Preg) and 7α-hydroxydehydroepiandrosterone (7α-OH-DHEA). Here we demonstrated the occurrence of ... 17. Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal ... RESULTS: Trabeculotomy was performed using a spatula-shaped hook in 17 eyes and a dual-blade hook in 15 eyes. Significant ...
alpha-numeric index A-Z followed by numbers. -has the number of postings to any particular term listed with term. -transparent ... HYDROXYPREGNENOLONE D 6.472.40.322.478.478.477 D4j00.t45. TETRAHYDROCORTISOL • D6.472.40J22.478.478.782 D4.a08.745. D6.4TZ.40. ... 39 contiguous alpha or alphanumeric characters D. Text word generation computer program for all ELHILL files (except CHEMLINE) ... alpha or alphanumeric 39 character string 2. special characters converted to blanks 3. hyphen exception rule stopword list „ e ...
Endocrinology, Diabetes & Metabolism Case Reports is an open-access, peer-reviewed title publishing case reports on common and rare conditions in all areas of clinical endocrinology, diabetes and metabolism
  • CYP17A1 also has 17,20-lyase activity, which converts 17-hydroxypregnenolone to dehydroepiandrosterone (DHEA). (medlineplus.gov)
  • Follow up with infants and young children about every 3-4 months for evaluation of height and weight, blood pressure, and laboratory monitoring (ie, pregnenolone, 17-hydroxypregnenolone, dehydroepiandrosterone [DHEA], plasma renin levels). (medscape.com)
  • Without 17α-hydroxylase activity, pregnenolone and progesterone are not converted to 17-hydroxypregnenolone or 17-hydroxyprogesterone, impairing production of glucocorticoids. (medlineplus.gov)
  • Exogenous glucocorticoid therapy suppresses adrenocorticotropic hormone (ACTH) secretion and decreases pregnenolone, 17-hydroxypregnenolone, and DHEA levels. (medscape.com)
  • Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. (jrheum.org)
  • Dozens of mutations in the CYP17A1 gene have been found to cause 17α-hydroxylase/17,20-lyase deficiency. (medlineplus.gov)
  • Reduction of these activities leads to partial 17α-hydroxylase/17,20-lyase deficiency, while total loss of these activities leads to the more severe form of the disorder known as complete 17α-hydroxylase/17,20-lyase deficiency. (medlineplus.gov)
  • A small number of CYP17A1 gene mutations have been found to cause isolated 17,20-lyase deficiency, which is characterized by abnormal sexual development without hypertension or hypokalemia. (medlineplus.gov)
  • As in 17α-hydroxylase/17,20-lyase deficiency (described above), impairment of 17,20-lyase activity disrupts sex hormone production, leading to abnormal development of internal or external reproductive organs and delayed or absent puberty in affected individuals. (medlineplus.gov)
  • The genetic and functional basis of isolated 17,20-lyase deficiency. (medlineplus.gov)
  • The enzyme has 17 alpha(α)-hydroxylase activity, converting pregnenalone to 17-hydroxypregnenolone and progesterone to 17-hydroxyprogesterone. (medlineplus.gov)
  • 1. PDG is converted to 17-hydroxypregnenolone (17-OHPREG) through the action of the enzyme 17-alpha-hydroxylase. (reproduction-online.org)
  • 2. 17-OHPREG is then converted to 17-hydroxyprogesterone (17-OHP) by the enzyme 3-beta-hydroxysteroid dehydrogenase (3β-HSD). (reproduction-online.org)
  • 3. Finally, 17-OHP is converted to progesterone by the enzyme 21-hydroxylase. (reproduction-online.org)
  • These mutations alter a region of the CYP17A1 protein that plays a role in the enzyme's 17,20-lyase function but not its 17α-hydroxylase function. (medlineplus.gov)
  • Both forms of adrenal hyperplasia are accompanied by elevated levels of 24-hour urinary 17-ketosteroids , the urinary metabolites of adrenal androgens. (medscape.com)
  • In contrast, hypertensive forms of adrenal hyperplasia (ie, 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency) are associated with suppressed PRA and, often, hypokalemia. (medscape.com)
  • Without 17α-hydroxylase activity, pregnenolone and progesterone are not converted to 17-hydroxypregnenolone or 17-hydroxyprogesterone, impairing production of glucocorticoids. (medlineplus.gov)
  • A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. (bvsalud.org)
  • Here, we examined in detail the processivity of the 17α-hydroxylation and lyase steps. (nih.gov)
  • Mutations associated with this condition reduce or eliminate both 17α-hydroxylase and 17,20-lyase activity. (medlineplus.gov)
  • A loss of 17,20-lyase activity impairs sex hormone production. (medlineplus.gov)
  • These mutations alter a region of the CYP17A1 protein that plays a role in the enzyme's 17,20-lyase function but not its 17α-hydroxylase function. (medlineplus.gov)
  • As a result, 17,20-lyase activity is severely reduced but 17α-hydroxylase activity is normal. (medlineplus.gov)
  • S)-Orteronel was three times more inhibitory toward the conversion of 17α-hydroxypregnenolone to DHEA than toward the 17α-hydroxylation of pregnenolone. (nih.gov)
  • IC50 values for (S)-orteronel were identical for blocking DHEA formation from pregnenolone and for 17α-hydroxylation, suggestive of processivity. (nih.gov)
  • Global kinetic modeling helped assign sets of rate constants for individual or groups of reactions, indicating that human P450 17A1 is an inherently distributive enzyme but that some processivity is present, i.e. some of the 17α-OH pregnenolone formed from pregnenolone did not dissociate from P450 17A1 before conversion to DHEA. (nih.gov)
  • The enzyme has 17 alpha(α)-hydroxylase activity, converting pregnenalone to 17-hydroxypregnenolone and progesterone to 17-hydroxyprogesterone. (medlineplus.gov)
  • High levels of 17-hydroxypregnenolone (Δ517OHP) are characteristic, but extra-adrenal conversion to 17-hydroxyprogesterone (17OHP) may lead to positive results on newborn screening tests. (nih.gov)